0f35c851-1cb8-4f75-a661-eae9111b7362
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 59
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.450
- MYC_TARGETS_V2+0.450
- E2F_TARGETS+0.430
- G2M_CHECKPOINT+0.340
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.280
- ADIPOGENESIS+0.260
- OXIDATIVE_PHOSPHORYLATION+0.240
- FATTY_ACID_METABOLISM+0.200
- ANGIOGENESIS+0.180
- BILE_ACID_METABOLISM+0.160
Top 10 suppressed
- INFLAMMATORY_RESPONSE-0.450
- TNFA_SIGNALING_VIA_NFKB-0.400
- TGF_BETA_SIGNALING-0.390
- ALLOGRAFT_REJECTION-0.350
- COMPLEMENT-0.330
- IL2_STAT5_SIGNALING-0.320
- P53_PATHWAY-0.280
- HEDGEHOG_SIGNALING-0.260
- INTERFERON_GAMMA_RESPONSE-0.260
- WNT_BETA_CATENIN_SIGNALING-0.260
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 34c0a7a8-8ce8-4a2a-9bce-939eb2f6f1d9 | — | — | 0.860 |
| 2 | ERR2208893 | — | — | 0.790 |
| 3 | 1cbc5c3a-eb0f-4492-9171-5e0a61923c33 | — | — | 0.765 |
| 4 | X0c9d8dde.aec7.4a95.b86c.da554465897b | — | cohortSQ1 | 0.763 |
| 5 | 2d8cab40-0dda-4d6d-a9ba-83a82a7e1c15 | — | — | 0.758 |
| 6 | SRR6013505 | — | cohortA4 | 0.756 |
| 7 | SRR12475170 | — | — | 0.755 |
| 8 | MBCproject_0227_T1_RNA | — | C | 0.752 |
| 9 | SRR17866857 | — | — | 0.750 |
| 10 | TCGA-UY-A9PD-01A-11R-A38B-07 | — | — | 0.746 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.450 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.450 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.430 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.340 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.280 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.260 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.240 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.200 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.180 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.160 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.160 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.140 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.140 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.130 | Inavolisib | — uncovered |
| PEROXISOME | 0.130 | Idelalisib | — uncovered |
| MYOGENESIS | 0.100 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.080 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.020 | Inavolisib | — uncovered |